The life science group, Lonza reports an overall solid Start to the year 2019. The newly-established Segment, Lonza Pharma Biotech & Nutrition (LPBN) proved to be a driving force. The Guidance in 2019 was confirmed.
LPBN achieved compared to the prior-year quarter, a "strong" result, exceeding expectations, according to the latest Basel on Thursday without Pay.
The zyklischere Segment of the Lonza Specialty Ingredients (LSI) have to fight, however, had challenges. Here are the shops would have developed worse than expected, and sales have remained at the same level as the first quarter of 2018. In addition, LSI is suffering from raw material shortages and interruptions in the supply chain.
Lonza had already announced in February, the ongoing business portfolio review, fast forward. Current information is likely to according to follow the current state in the second half of 2019, held Lonza on Thursday.
confirmed, reaffirmed its full-year targets for 2019. See this for the current year, sales growth in the mid to high single-digit range, as well as a core EBITDA margin on a "consistently high level". 2018, called the operating profit margin stood at 27.3 per cent.
In force, the medium-term targets for 2022: to the referred to year, sales are expected to rise to 7.1 billion Swiss francs (2018: 5.5 billion) and core EBITDA margin at 30.5 percent.
It is the first interim report, the Lonzas new CEO Marc radio presenting. And it is at the same time the last "Business Update", the Lonza in addition to the annual and half - yearly reporting. In the future no water will be on the first and third quarter reports was made.
Created: 18.04.2019, 07:24 PM